Clinical advice: ATAGI statement on use of Dengvaxia® for Australians
The Australian Technical Advisory Group on Immunisation (ATAGI) has developed advice for immunisation providers regarding the administration of Dengvaxia® for Australians. It includes information about the dengue virus, as well as use, efficacy and safety of the dengue vaccine in Australians.
The Australian Technical Advisory Group on Immunisation (ATAGI) has provided advice to support immunisation providers in their use of Dengvaxia® for Australians.
The ATAGI advice indicates:
- the dengue vaccine, Dengvaxia®, is NEVER indicated for primary prevention of initial dengue infection
- Dengvaxia® is potentially harmful and should not be used in people who have never had a dengue infection
- Dengvaxia® should only be used to prevent subsequent, more serious secondary infections in specific groups
- vaccination in individuals who do not have laboratory, clinical, and epidemiological evidence consistent with previous dengue infection appears to increase the risk of hospitalisation and serious disease
- Australian travellers are NOT recommended to receive Dengvaxia® for short-term stays in dengue-endemic areas, even in people who have had previous dengue infection, as the risks outweigh any potential benefits
- vaccination with Dengvaxia® should only be considered for Australians on very rare occasions when all of the following conditions are met:
- aged 9-45 years; AND
- have had previous dengue infections; AND
- are intending to reside in highly dengue-endemic regions for an extended period; AND
- only if the potential benefits are deemed to outweigh the risks.
Please see ATAGI’s clinical advice on Dengvaxia® for Australians in full.